Quantcast

Latest Thalassemia Stories

2014-03-19 08:28:51

TORRANCE, Calif., March 19, 2014 /PRNewswire/ -- Emmaus Life Sciences, Inc. (the "Company," or "Emmaus"), a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and...

2014-01-09 08:26:57

--Partnership to Focus on Developing Novel Therapies for Sickle Cell Disease and Beta-Thalassemia-- CAMBRIDGE, Mass. and RICHMOND, Calif., Jan. 9, 2014 /PRNewswire/ -- Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The...

2014-01-08 20:21:27

- Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) EAST HANOVER, N.J., Jan. 8, 2014 /PRNewswire/ -- Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient health and supports patient medication adherence programs integral to this goal. These include outreach by pharmacies aimed at helping patients appropriately take their medicines as prescribed...

2014-01-08 08:27:43

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will present an update on Sangamo's clinical and preclinical ZFP Therapeutic(®) programs and upcoming milestones, as well as an overview of the Company's business strategy at the 32(nd) Annual J.P. Morgan Healthcare Conference on Thursday, January 16(th) at 11:00 am PT in San Francisco. (Logo:...

2014-01-07 08:30:43

TORRANCE, Calif., Jan. 7, 2014 /PRNewswire/ -- Emmaus Medical, Inc. (the "Company," or "Emmaus"), a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in...

2013-12-09 14:00:42

New research presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands of patients worldwide. Sickle cell disease (SCD) is an inherited, chronic disorder affecting nearly 100,000 Americans. Instead of producing healthy red blood cells,...

2013-11-04 14:11:33

In-depth look at living with thalassemia A CHEO-led multi-site North American study, headed by Dr. Robert Klaassen, lead investigator at CHEO and associate professor in the University of Ottawa's Department of Pediatrics, has confirmed the validity and reliability of a quality of life measurement tool for children and adults with thalassemia major. The tool was created between 2006 and 2009 through the combined efforts of CHEO, the Hospital for SickKids and Laurentian University....

2013-11-01 23:04:25

CCBF Gala Raises Over $1 Million for Children’s Cancer and Blood Disorders New York, NY (PRWEB) November 01, 2013 The Children’s Cancer & Blood Foundation (CCBF) hosted its annual “Breakthrough Ball” benefit gala on Tuesday evening, October 29, 2013 in the Grand Ballroom of the Plaza Hotel. A stunning success, the evening raised over $1 million to provide medication, chemotherapy and other life-saving treatments to thousands of children at the Division of Pediatric Hematology...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related